{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T07:54:13Z","timestamp":1786866853543,"version":"build-2736575974"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Mayo Clinic Cancer Center, Department of Hematology Oncology"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-024-01134-3","type":"journal-article","created":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T08:07:41Z","timestamp":1725523661000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9314-9933","authenticated-orcid":false,"given":"Ricardo D.","family":"Parrondo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy R.","family":"LaPlant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin J.","family":"Flott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diedre","family":"Arrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustin","family":"Chapin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jade","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0597-8123","authenticated-orcid":false,"given":"Saurav","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5950-4620","authenticated-orcid":false,"given":"Vivek","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asher A.","family":"Chanan-Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8377-8111","authenticated-orcid":false,"given":"Sikander","family":"Ailawadhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,5]]},"reference":[{"key":"1134_CR1","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1182\/blood-2023-187339","volume":"142","author":"NS Joseph","year":"2023","unstructured":"Joseph NS, Kaufman JL, Dicamillo S, Roberts D, Gupta VA, Hofmeister CC, et al. Comparison of response and survival outcomes in standard- and high-risk newly diagnosed transplant-eligible multiple myeloma (NDMM) patients treated with lenalidomide, bortezomib and dexamethasone (RVD) versus daratumumab, lenalidomide, bortezomib and dexamethasone (D-RVD). Blood. 2023;142:647.","journal-title":"Blood"},{"key":"1134_CR2","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1007\/s00262-013-1493-8","volume":"62","author":"SM Collins","year":"2013","unstructured":"Collins SM, Bakan CE, Swartzel GD, Hofmeister CC, Efebera YA, Kwon H, et al. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol Immunother. 2013;62:1841\u20139.","journal-title":"Cancer Immunol Immunother"},{"key":"1134_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00357-4","volume":"10","author":"MA Dimopoulos","year":"2020","unstructured":"Dimopoulos MA, Lonial S, White D, Moreau P, Weisel K, San-Miguel J, et al. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J. 2020;10:91.","journal-title":"Blood Cancer J"},{"key":"1134_CR4","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373:621\u201331.","journal-title":"N Engl J Med"},{"key":"1134_CR5","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","volume":"379","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2018;379:1811\u201322.","journal-title":"N Engl J Med"},{"key":"1134_CR6","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1200\/JCO.21.02815","volume":"41","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, et al. Elotuzumab plus pomalidomide and dexamethasone for relapsed\/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT-3 trial. J Clin Oncol. 2023;41:568\u201378.","journal-title":"J Clin Oncol"},{"key":"1134_CR7","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.3389\/fimmu.2018.02134","volume":"9","author":"N van de Donk","year":"2018","unstructured":"van de Donk N, Usmani SZ. CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance. Front Immunol. 2018;9:2134.","journal-title":"Front Immunol"},{"key":"1134_CR8","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1080\/10428194.2019.1688324","volume":"61","author":"E Hoylman","year":"2020","unstructured":"Hoylman E, Brown A, Perissinotti AJ, Marini BL, Pianko M, Ye JC, et al. Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma. Leuk Lymphoma. 2020;61:691\u20138.","journal-title":"Leuk Lymphoma"},{"key":"1134_CR9","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","volume":"33","author":"UH Gandhi","year":"2019","unstructured":"Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33:2266\u201375.","journal-title":"Leukemia"},{"key":"1134_CR10","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u201346.","journal-title":"Lancet Oncol"},{"key":"1134_CR11","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1080\/10428194.2023.2284088","volume":"65","author":"MJ Rees","year":"2024","unstructured":"Rees MJ, Kumar S. BCMA-directed therapy, new treatments in the myeloma toolbox, and how to use them. Leuk Lymphoma. 2024;65:287\u2013300.","journal-title":"Leuk Lymphoma"},{"key":"1134_CR12","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1182\/blood-2019-129021","volume":"134","author":"AF Grajales-Cruz","year":"2019","unstructured":"Grajales-Cruz AF, Rodriguez Arocho CI, Rose A, Shapiro J, Finley-Oliver E, Shain KH, et al. Elotuzumab in combination with an immunomodulatory agent (IMID) in patients with multiple myeloma refractory to imids and\/or daratumumab: a single-institution analysis. Blood. 2019;134:3183.","journal-title":"Blood"},{"key":"1134_CR13","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3322\/caac.21718","volume":"72","author":"AN Giaquinto","year":"2022","unstructured":"Giaquinto AN, Miller KD, Tossas KY, Winn RA, Jemal A, Siegel RL. Cancer statistics for African American\/Black people 2022. CA Cancer J Clin. 2022;72:202\u201329.","journal-title":"CA Cancer J Clin"},{"key":"1134_CR14","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/bjh.18185","volume":"198","author":"LJ Costa","year":"2022","unstructured":"Costa LJ, Hungria V, Mohty M, Mateos MV. How I treat triple-class refractory multiple myeloma. Br J Haematol. 2022;198:244\u201356.","journal-title":"Br J Haematol"},{"key":"1134_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00886-8","volume":"13","author":"CJ Ferreri","year":"2023","unstructured":"Ferreri CJ, Hildebrandt MAT, Hashmi H, Shune LO, McGuirk JP, Sborov DW, et al. Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer J. 2023;13:117.","journal-title":"Blood Cancer J"},{"key":"1134_CR16","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1182\/bloodadvances.2024012773","volume":"8","author":"B Puertas","year":"2024","unstructured":"Puertas B, Fern\u00e1ndez-S\u00e1nchez A, Alejo E, Rey-B\u00faa B, Mart\u00edn-L\u00f3pez AA, P\u00e9rez-L\u00f3pez E, et al. A research center\u2019s experience of T-cell\u2013redirecting therapies in triple-class refractory multiple myeloma. Blood Adv. 2024;8:3478\u201387.","journal-title":"Blood Adv"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01134-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01134-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01134-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T08:07:46Z","timestamp":1725523666000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01134-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,5]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1134"],"URL":"https:\/\/doi.org\/10.1038\/s41408-024-01134-3","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,5]]},"assertion":[{"value":"22 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"BRL, JE, AF, CJF, DA, DC, JB, SD and VR have no conflicts of interest to declare. RDP serves on the advisory board for Sanofi Aventis and Astra Zeneca and has received research funding from Bristol Myers Squibb Foundation and GlaxoSmithKline. SA has provided consultancy for Celgene, Amgen, Janssen and Takeda, and has received research funding from Pharmacyclics, Cellectar and Janssen. AAC-K has received research funding from Xencor Pharmacyclics, Merck, Janssen, Ascentage and Millennium.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study protocol and all amendments were reviewed and approved by the Institutional Review Board at Mayo Clinic Florida (IRB # 18-003574). The study was conducted in accordance with the International Conference on Harmonisation Good Clinical Practice guidelines, the principles originating from the Declaration of Helsinki, and study site-specific regulations. All patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"152"}}